NCT05307341View on ClinicalTrials.gov

Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)

PHASE4UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Pain
Interventions
DRUG

sufentanil

One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.

Trial Locations (1)

85015

RECRUITING

The CORE Institute Specialty Hospital, Phoenix

Sponsors

Lead Sponsor

More Foundation
All Listed Sponsors
lead

More Foundation

OTHER

NCT05307341 - Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) | Biotech Hunter | Biotech Hunter